Skip to main content

Britain gets ready for roll-out of Pfizer's COVID-19 vaccine this week

LONDON (Reuters) - Britain is preparing to become the first country to roll out the Pfizer/BioNTech COVID-19 vaccine this week, initially making the shot available at hospitals before distributing stocks to doctors’ clinics, the government said on Sunday.

The first doses are set to be administered on Tuesday, with the National Health Service (NHS) giving top priority to vaccinating the over-80s, frontline healthcare workers and care home staff and residents.

Britain gave emergency use approval for the vaccine developed by Pfizer and BioNTech last week - jumping ahead in the global race to begin the most crucial mass inoculation programme in history.

In total, Britain has ordered 40 million doses - enough to vaccinate 20 million people in the country of 67 million.

About 800,000 doses are expected to be available within the first week.

Initial doses that have arrived from Belgium are being stored in secure locations across the country, where they will be quality checked, the health ministry said.

The Pfizer/BioNTech vaccine has onerous storage requirements. It needs to be kept at -70C (-94F) and only lasts five days in a regular fridge.

For that reason, the health ministry said the vaccine would first be administered in 50 hospitals. It said it would take a few hours to defrost each vaccine and prepare it for use.

NHS England has written to general practitioners, telling them to get ready to start giving vaccinations through local doctors’ services from Dec. 14.

Rather than run clinics in individual surgeries, groups of local doctors will operate more than 1,000 vaccination centres across the country, the government said.

Boxes of the vaccine contain five packs of 975 doses, but special regulatory approval is needed to split them up. A senior medical official has said that while he was hopeful it would be possible to split the packs and deliver straight to care homes, it was not guaranteed.

Britain is among the first nations to roll out vaccinations outside the context of a clinic trial, raising hopes that the tide could soon turn against a virus that has killed nearly 1.5 million people globally and hammered the world economy.

Russia began distributing its Sputnik V COVID-19 vaccine through 70 clinics in Moscow on Saturday, although the shot has not finished its final trials.

Comments

New comments are not allowed.

Popular posts from this blog

Britain's navy in the event of a no-deal Brexit to defend fishing waters

LONDON (Reuters) - In the event that the Brexit transition phase ends on Dec. 31 without an agreement on future relations with the European Union, four Royal Navy patrol ships are on standby to defend Britain's fishing waters, the Ministry of Defence (MOD) said. The step attracted criticism from lawmakers within the Conservative Party of British Prime Minister Boris Johnson, but was brushed off by the French government. "Keep calm and carry on," said an Elysée official, using a British wartime slogan. Where no trade agreement is reached, questions are raised about potential skirmishes between British and international fishing vessels, with current transitional rules allowing EU boats access to British waters set to expire by the end of the year. "An MOD spokesman said The MOD has carried out comprehensive training and preparation to ensure that Defence is ready at the end of the Transition Phase for a variety of scenarios. The 80-meter-long navy vessels would h...
Post a Comment
Read more

The CEO of AstraZeneca plans to conduct the latest global COVID-19 vaccine trial: Bloomberg

(Reuters) - An additional global trial to test the effectiveness of its COVID-19 vaccine using a lower dose is likely to be conducted by AstraZeneca, its chief executive was quoted as saying on Thursday amid concerns about the outcome of its late-stage review. AstraZeneca could start a new study to test a lower dose of its vaccine that worked better than a full dosage, Pascal Soriot told Bloomberg News, instead of adding the trial to an existing U.S. phase. "We have to validate this now that we have discovered what looks like a better efficacy, so we need to do an additional study," he said, adding that the latest, likely global, study could be quicker because it would require less subjects as the effectiveness was already established to be high. The news comes as AstraZeneca faces concerns about its success rate that some analysts claim could impede its chances of securing rapid regulatory approval from the U.S. and EU. Several scientists have raised concerns about the r...
Post a Comment
Read more

In 'challenging point' Brexit trade negotiations, British minister says

LONDON (Reuters) - Brexit trade negotiations are in a difficult process, and only if the European Union understands that Britain is a sovereign nation will an agreement be reached, said Business Secretary Alok Sharma. "We're at a critical stage," Sky TV told Sharma. "It is fair to say that we are in a difficult phase, that there are still some difficult problems to solve." "We have always said right from the beginning of this process that only if the EU recognizes that the UK is a sovereign independent nation can an agreement be reached," Sharma said. "It is on the basis of that a deal will be done."
Post a Comment
Read more